Sentences with phrase «works in tumor»

«If you show it works in tumor studies, I have no trouble with it being the guideline for tumor studies,» he says.

«Researchers are using newer technologies to look directly into tumors,» she says, «to make sure immunotherapies induce a response that works in the tumor.»

Drugs like pembrolizumab boost the response in tumors where immune cells are present but don't work in tumors where there is no immune response to boost.

He says that the mechanism is unlikely to work in all tumor types or metastases, but that it is definitely worth exploring its potential ability to turn some fatal cancers into chronic diseases.

Not exact matches

The Kamens claim the main thing that distinguishes their foundation from other brain tumor foundations is their focus on pediatric brain cancer specifically, as well as their close ties with pharmaceutical and biotech companies working in the fields of immunotherapy and target gene therapy.

Kneaders found a partner in Huntsman Cancer Institute, an organization that is working with the University of Utah to conduct research into how DNA from elephants, which are resistant to tumors, could be used to cure childhood cancer.

Previous work in Weinberg's lab had shown that after a tumor forms in one part of the body, some of the cancer cells undergo EMT, Mani explains.

For some years now, a new class of drugs called antibody - drug conjugates (ADCs) have been used, which work in two ways: they consist of an antibody that binds selectively to the tumor cell receptor and interrupts the signal to propagate; they also act as a transport vehicle for a chemical substance that enters the cancer cells with the antibody and triggers their death.

In a recent study, working with a team of researchers, Danino demonstrated that bacteria in pancreatic tumors degrade a chemotherapy drug — Gemcitabine — most commonly used to treat patients who have pancreatic canceIn a recent study, working with a team of researchers, Danino demonstrated that bacteria in pancreatic tumors degrade a chemotherapy drug — Gemcitabine — most commonly used to treat patients who have pancreatic cancein pancreatic tumors degrade a chemotherapy drug — Gemcitabine — most commonly used to treat patients who have pancreatic cancer.

The work, reported online today in Science, could one day lead to a tool for routinely screening people and catching tumors before they cause symptoms, when chances are best for a cure.

«Our work strongly supports that cancer stem cells are the main source of growth in these tumors and, as such, should be considered promising targets for treatment,» says Mario Suvà, MD, PhD, of the MGH Department of Pathology, co-senior author of the Nature paper.

For some cancer patients, viruses engineered to zero in on tumor cells work like a wonder drug.

The virus, redesigned using sophisticated protein engineering techniques, works: With its shield and its adapter, these viral gene shuttles efficiently infected tumor cells in laboratory animals.

In demonstrating that FOXO4 works to prevent the spread of cancerous tumors by binding to and inhibiting the protein RUNX2, the team identified a circuit that controls metastatic progression in prostate canceIn demonstrating that FOXO4 works to prevent the spread of cancerous tumors by binding to and inhibiting the protein RUNX2, the team identified a circuit that controls metastatic progression in prostate cancein prostate cancer.

«Different types of cancer cells with different strengths and weaknesses are both present in the tumor at the same time and can work together to spread faster and more efficiently.

Working with colleagues at St. Vincent's Hospital in Sydney, Martin identified two individuals who had the characteristics of hereditary nonpolyposis colorectal cancer, which is usually caused by a mutation that inactivates one of a person's two copies of the tumor suppressor gene MLH1, but who showed no signs of mutation.

Maria Zajac - Kaye, Ph.D., an associate professor in the College of Medicine's department of anatomy and cell biology, and Rony François, an M.D. / Ph.D. student who works with her, found a new drug combination that inhibits one form of pancreatic cancer tumor and kills its cells.

The company is also working on a similar test in solid tumors for early diagnosis of relapse, and is developing tests that will help diagnose some lymphomas that are notoriously tricky to detect.

Cells suspended in a stiff matrix were more likely to work their way through the matrix to other side of a serum gradient, analogous to how metastasizing cancer cells break free from their tumors.

A case of cancer was diagnosed in his family, and Delahaye decided to spend his postdoc working on tumor immunogenetics in the laboratory of Laurence Zitvogel at the Institut Gustave Roussy in Paris.

«Despite the low infection levels of mouse cells with oHSV, we were able to cause a delay in tumor growth in one of the cancer models and even cure many of the mice in a second model,» said first author Jennifer Leddon, who conducted much of the laboratory work during a research experience in the Center for Childhood Cancer and Blood Diseases.

«The effective immune response didn't happen in every tumor model we tested, so we still need to figure out exactly what triggered the tumor shrinkage and how to predict which tumors will shrink in response to virotherapy,» said Leddon, who is also working toward her medical and doctoral degrees at the University of Cincinnati.

But as noted in a recent Science news story, targeted therapies don't work as well on solid tumors, which usually develop resistance and start growing again.

Previous work on cartilage tumors has been done using models based on genetic mutations that occurred only rarely in enchondromas; however, IDH mutations are present in a high percentage of enchondromas.

Dr. Preul directs the Neurosurgery Research Laboratory of the Barrow Neurosurgical Institute, which has carried out the pioneer work in applying and developing confocal laser endomicroscopy for brain tumors.

The work demonstrates that BRAF - mutated melanoma requires autophagy for tumor development and blocking autophagy could have therapeutic value, particularly in combination with BRAF inhibition.

«Hodgkin lymphoma is unusual among cancers in that it consists of a small number of tumor cells in a sea of inflammatory cells and immune system cells, including T cells that don't work very effectively.»

His work on RMP - 7 came to naught in 1998: «We demonstrated in the Phase 1 and 2 trials that when RMP - 7 was delivered directly into the carotid artery that fed the tumor, we could open the blood - brain barrier and get clinical responses to the chemo.

The class of medications that he conceived, known as immune checkpoint inhibitors, works counterintuitively: By turning off one of the immune system's built - in safeguards, the inhibitors allow T cells — the system's foot soldiers — to attack tumors more effectively.

«Now we're investigating how the protein works in order to be able to develop a drug that could prevent tumor metastasis.»

Frank Ruscetti, who had discovered HTLV - 1 while working in Robert Gallo's Laboratory of Tumor Cell Biology at the NCI in 1980, was Mikovits's primary collaborator.

In a previous study, his team worked with other collaborators to identify the potential role of extra copies of the tumor suppressor gene (p53) that increase the elephant's ability to eliminate pre-cancerous cells with DNA damage.

In a study published in the Journal of NeuroOncology, TGen researchers report that PPF works to limit the spread of glioblastoma multiforme, or GBM — the most common primary tumor of the brain and central nervous system — by targeting a protein called TROIn a study published in the Journal of NeuroOncology, TGen researchers report that PPF works to limit the spread of glioblastoma multiforme, or GBM — the most common primary tumor of the brain and central nervous system — by targeting a protein called TROin the Journal of NeuroOncology, TGen researchers report that PPF works to limit the spread of glioblastoma multiforme, or GBM — the most common primary tumor of the brain and central nervous system — by targeting a protein called TROY.

«By understanding how stress accelerates invasion in aggressive breast tumor cells, this work will inform future studies into whether beta - blockers could be a useful adjuvant therapy in the treatment of some aggressive breast cancers.»

The work also reinforces the importance of finding tumor cell clusters in the blood as a mechanism of detecting cancer metastasis earlier.

«We had a hypothesis about how these treatments would work together, and when we did biopsies of patients» tumors we found that they were cooperating in just the way we thought they would,» says lead author Antoni Ribas, director of the Immunology Program at the UCLA Jonsson Comprehensive Cancer Center.

Previous work also suggested synergistic impact of isoprenoids on tumor growth, a finding remaining to be confirmed in prostate cancer.

The Oncotarget study demonstrated that Brenner's antibody worked in animal models of tumors that made cadherin - 11.

Combining their strategy with an existing immunotherapy treatment that works by releasing the «brakes» on immune cells, they found they could shrink melanoma tumors, and prolong survival in preclinical models for melanoma.

«We have shown that our molecule works on cancer cells in the lab, but the next step is to see if it works on real tumors in animals.

«Our work paves the way to discovering many more of these unusual RNAs and how they contribute to cancer, which could reveal new mechanisms and druggable pathways involved in tumor progression.»

Published in Nature Photonics, this work might lay a foundation for in vivo experiments that use light in biomedical imaging, optogenetics, tumor treatment, and for recharging implanted medical devices.

The finding warrants research into adding drugs that could prevent the cancer from hijacking patients» repressive gene regulatory machinery, which might allow the original therapy to work long enough to eradicate the tumor, the researchers report in their National Institutes of Health - funded study, published in the current issue of Science Translational Medicine.

Working in mouse models of primary, non-metastatic tumors, the researchers increased the production of the tRNAs, and found that these cells became much more invasive and metastatic.

How aspirin works is a longstanding puzzle, but Harris and others theorize that it may help inhibit cancer by blocking cyclooxygenase - 2, or COX - 2, an enzyme commonly found in malignant tumors.

«Radioimmunotherapy not only worked against these cancers but, in addition, the radioactivity was confined entirely to the tumor masses, leaving healthy tissues undamaged,» said senior study co-author Ekaterina Dadachova, an associate professor of nuclear medicine and of microbiology and immunology at Einstein.

«The use of a mouse tumor - derived matrix would limit any future applications of these organoid technologies in humans, and this work opens the door to research directed specifically for clinical applications,» noted Asma Nusrat, study co-author and the Aldred Scott Warthin Professor and Director of Experimental Pathology in the University of Michigan's School of Medicine.

They work particularly well if the cancer cells they attack already have defects in the corresponding DNA repair pathways, as it frequently occurs in breast cancer and other tumors.

Drugs like fluorouracil, oxaliplatin and irinotecan work by mimicking and damaging DNA molecules, or inhibiting enzymes involved in cell and DNA replication, slowing the uncontrolled growth of tumor cells.

In the future, their work could help scientists to better understand the formation of tumors.